Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

HK Type 4 license through Ballingal Investment Advisors Ltd. 

I'm a highly experienced sell-side analyst with in excess of 22 years of covering Asia Pacific equities, the past 19 years immersed in event strategies encompassing M&A risk arbitrage, directional long/short, stub trades and restructuring.  

My background also includes accountancy (liquidation/bankruptcy/receivership) earlier in my career and as a chief financial officer of a global commodity company based in the US and Mexico.

Pan-Asia Catalysts/Events

Acotec (6669 HK): Current Proration of 82.7%

Acotec/Boston Scientific: Even Higher Proration

Acotec Scientific Holdings: Boston Scientific's Partial Offer

Acotec (先瑞达) IPO Trading: Expect Poor Debut Performance

Quiddity Advisors

Event-Driven

Acotec Scientific Holdings / Event-Driven

<ul>
<li>On the 12 December, <strong><a href="https://www.smartkarma.com/entities/acotec-scientific-holdings-limited" target="_blank" data-smartkarma-citation="entities:32176:1" rel="noopener">Acotec Scientific (6669 HK)</a></strong> announced a HK$20/share partial Offer from Boston Scientific, a 31.6% premium to last close, but below August 2021's IPO price of HK$23.80/share.  </li>
<li>Boston Scientific will acquire at least 156.7mn shares (50.01%), up to 203.7mn (65%). Irrevocables total 60.14%, comprising shares held by CA Medtech/CPE Investment, Jing Li (chairman, CEO), and Bliss Way.</li>
<li>The Composite Doc is now out and the Offer is open for acceptances. This Offer is done. The key question is the final proration. </li>
</ul>


On the 12 December, Acotec Scientific (6669 HK) announced a HK$20/share partial Offer from Boston Scientific, a 31.6% premium to last close, but below August 2021's IPO price of HK$23.80/share.  
Boston Scientific will acquire at least 156.7mn shares (50.01%), up to 203.7mn (65%). Irrevocables total 60.14%, comprising shares held by CA Medtech/CPE Investment, Jing Li (chairman, CEO), and Bliss Way.
The Composite Doc is now out and the Offer is open for acceptances. This Offer is done. The key question is the final proration. 


Acotec (6669 HK): Boston Scientific's Partial Offer Open For Tendering